MD/PhD, Associate Professor @JHSPH_HPM @JohnsHopkinsSPH. Working to make prescription drugs more affordable, accessible, and available to people who need them.
Today the discussion is about fees that PBMs pay for consultants and brokers that help health insurance plans select a PBM. Should those fees be prohibited ?
I’ll be testifying on this topic at a Congressional hearing in a few minutes . Live stream here
https://t.co/REAVK2DP4p
Busy meeting today at the #WhiteHouse to discuss incentives for #MadeInAmerica drugs.
How to can we identify which 💊 drugs are #MadeInAmerica 🇺🇸? The @JohnsHopkins prescription drug supply chain data dashboard 📝📈can help — https://t.co/BM8HxI5dhp
Pharmaceutical supply chain issues in the U.S. have become a health and national security threat. In the latest #SpeedBrief, @JohnsHopkinsSPH's Mariana Socal discusses Hopkins' answer to this growing problem.
#supplychain#drugshortages
Congratulations to the winners of the 2025 Sommer Klag Advocacy Impact Awards: Harry Barbee, PhD, and Mariana Socal, MD, PhD🎉.
Their pitch presentations showcased strong potential to create meaningful shifts in policy and practice within their fields👏🏽.
We are all set for tomorrow’s @theNASEM Workshop on #pharmaceutical#supplychain at the Hopkins Bloomberg center in Washington DC!🎓 The view is amazing and the program will be even better !
More info here: https://t.co/epA85402Hp
If the peer-reviewer gods are watching , I hope they noticed that I finished all the reviews I had on my plate today. 😇 Now could they please make the people reviewing my papers finish their reviews too?!? Would be a true gift , thank you
Today the spotlight is on the 1st year of the Inflation Reduction Act and its #drugpricing provisions. Thank you @gwlaw for inviting me to lead a very illustrious panel. Great discussion!
With @RESachs@ConorSheehey and Gregory Daniel from @EliLillyandCo
Ozempic (semaglutide) is one of the drugs with the biggest affordability challenges today. It is used to treat type 2 diabetes and to protect these patients from cardiovascular problems. Given the high prevalence of diabetes in the US, every 💰dollar counts (5/5)
Canada seems about to get generics for Ozempic (semaglutide), possibly as soon as January 2026. This is in stark contrast to the US, where generics will have to wait until at least 2032. What is the difference ? (1/5)
https://t.co/wSwW8qOl9I
Should we have the same system as Canada ? Not necessarily, but this is an important lesson that our drug patent system must be revisited. - there are a few bills introduced in Congress to change this system , and they should receive more of our attention. (4/5)
How to improve the affordability of pharmaceutical treatments for #diabetes? This call for action is now available for free download at @DiabetesCareADA
https://t.co/ivdH3QOS9f